Protagenic Cash Per Share from 2010 to 2024

PTIXW Stock  USD 0.01  0  11.11%   
Protagenic Therapeutics Cash Per Share yearly trend continues to be fairly stable with very little volatility. Cash Per Share will likely drop to 0.89 in 2024. During the period from 2010 to 2024, Protagenic Therapeutics Cash Per Share regression line of quarterly data had mean square error of  17,839 and geometric mean of  4.35. View All Fundamentals
 
Cash Per Share  
First Reported
2010-12-31
Previous Quarter
0.93357977
Current Value
0.89
Quarterly Volatility
181.43057062
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Protagenic Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagenic Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.8 K, Interest Expense of 137.6 K or Selling General Administrative of 1.1 M, as well as many indicators such as Price To Sales Ratio of 0.28, Dividend Yield of 0.0 or PTB Ratio of 1.11. Protagenic financial statements analysis is a perfect complement when working with Protagenic Therapeutics Valuation or Volatility modules.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Latest Protagenic Therapeutics' Cash Per Share Growth Pattern

Below is the plot of the Cash Per Share of Protagenic Therapeutics over the last few years. It is Protagenic Therapeutics' Cash Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protagenic Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.06 X10 Years Trend
Slightly volatile
   Cash Per Share   
       Timeline  

Protagenic Cash Per Share Regression Statistics

Arithmetic Mean90.77
Geometric Mean4.35
Coefficient Of Variation199.89
Mean Deviation140.19
Median2.34
Standard Deviation181.43
Sample Variance32,917
Range441
R-Value(0.70)
Mean Square Error17,839
R-Squared0.50
Significance0
Slope(28.59)
Total Sum of Squares460,839

Protagenic Cash Per Share History

2024 0.89
2023 0.93
2022 1.85
2021 2.81
2020 0.26
2019 0.31
2018 0.24

About Protagenic Therapeutics Financial Statements

Protagenic Therapeutics investors use historical fundamental indicators, such as Protagenic Therapeutics' Cash Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protagenic Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash Per Share 0.93  0.89 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Protagenic Stock Analysis

When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.